Hormonal
GLP-1 receptor agonists (GLP-1RAs) reduce major adverse cardiovascular events (MACE), including cardiovascular mortality, myocardial infarction, and stroke, in patients with type 2 diabetes and high cardiovascular risk.
If you have Type 2 Diabetes and existing heart disease or high risk, GLP-1 receptor agonists (like Semaglutide or Liraglutide) are proven to lower your risk of heart attack, stroke, and cardiovascular death. This benefit is independent of weight loss in some cases, though weight loss often accompanies it. Discuss these options with your doctor, especially if you are at high risk.
Cardiovascular outcome trials (CVOTs) in people living with type 2 diabetes mellitus and obesity have confirmed the cardiovascular benefits of glucagon-like peptide 1 receptor agonists (GLP-1RAs), including reduced cardiovascular mortality, lower rates of myocardial infarction, and lower rates of stroke.
Why this rating
Based on multiple large-scale, randomized, placebo-controlled cardiovascular outcome trials (LEADER, SUSTAIN-6, etc.).
Source
GLP-1 receptor agonist-based therapies and cardiovascular risk: a review of mechanisms
Neerav Mullur et al. · Journal of Endocrinology · 2024
DOI 10.1530/joe-24-0046
More from this paper
- Dual-agonists (GLP-1R/GIPR) and tri-agonists (GLP-1R/GIPR/GCGR) provide superior weight loss and cardiometabolic risk factor improvement (blood pressure, lipids) compared to GLP-1RAs alone, though their direct impact on hard cardiovascular outcomes (MACE) is still under investigation.Good
- Some GLP-1RAs (e.g., Lixisenatide, Exenatide, oral Semaglutide) show neutral cardiovascular outcomes in patients with Type 2 Diabetes, suggesting that not all GLP-1RAs provide cardiovascular protection.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →